Hennion & Walsh Asset Management, Inc. Aldeyra Therapeutics, Inc. Transaction History
Hennion & Walsh Asset Management, Inc.
- $2.1 Billion
- Q4 2024
A detailed history of Hennion & Walsh Asset Management, Inc. transactions in Aldeyra Therapeutics, Inc. stock. As of the latest transaction made, Hennion & Walsh Asset Management, Inc. holds 85,448 shares of ALDX stock, worth $505,852. This represents 0.02% of its overall portfolio holdings.
Number of Shares
85,448
Previous 87,036
1.82%
Holding current value
$505,852
Previous $469,000
9.17%
% of portfolio
0.02%
Previous 0.02%
Shares
7 transactions
Others Institutions Holding ALDX
# of Institutions
122Shares Held
36.7MCall Options Held
196KPut Options Held
142K-
Perceptive Advisors LLC New York, NY9.28MShares$54.9 Million1.31% of portfolio
-
Knoll Capital Management, LLC Miami, FL5.48MShares$32.4 Million14.56% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.76MShares$22.2 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.62MShares$21.4 Million0.0% of portfolio
-
Kennedy Capital Management, Inc. St Louis, MO1.88MShares$11.1 Million0.24% of portfolio
About Aldeyra Therapeutics, Inc.
- Ticker ALDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,323,100
- Market Cap $345M
- Description
- Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...